• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 160

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Pα+ Psychedelic Bulletin #211: AbbVie Officially Enters Psychedelics; atai-Beckley’s 5-MeO-DMT Scores Breakthrough Therapy Designation; California Bill Signed

Q3’25 Investor Survey: What are Investors Most Concerned About?

A European Model: Robert Schoevers on the Continent’s Growing Psychedelic Research Agenda

Psychedelic Insights Playground

Brad Adams PhD – LAMPS

HAVN Life Enters Supply Agreement with MPB Group Inc.

PsyBio Therapeutics to Seek Approval of Proposed Share Consolidation at Annual...

Numinus Unveils New Logo and Brand Identity

Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking...

Digging Up Druggable Targets: Psilocybin Efficacy in a Model of OCD

PT332 – James Lanthier – Patentability, Capitalism, and The Next Generation...

Incannex to Present at the H.C. Wainwright First Annual Mental Health...

Psychedelic Bulletin #108 – COMPASS Survives Patent Challenges; MindMed Secures Candyflipping...

Field Trip Health Ltd. to Present at the H.C. Wainwright 1st...

Mindset Pharma and Top Psychiatric Research Hospital, CAMH, Enter Innovative Collaboration...

1...159160161...300Page 160 of 300

EDITOR PICKS

Pα+ Psychedelic Bulletin #211: AbbVie Officially Enters Psychedelics; atai-Beckley’s 5-MeO-DMT Scores...

Q3’25 Investor Survey: What are Investors Most Concerned About?

A European Model: Robert Schoevers on the Continent’s Growing Psychedelic Research...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©